Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmaniaga BhdXKLS:7081 +1.72%45 Return-on-Tangible-Equity is 42.23% as of Mar. 2026, which is 62% above its 10-year median of 26.13. GuruFocus rates XKLS:7081 with a GF Score™ of 45/100 and a GF Value™ of RM0.69 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 112 Medical Distribution companies, Pharmaniaga Bhd ranks better than 86.61% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Pharmaniaga Bhd's annualized net income for the quarter that ended in Mar. 2026 was RM126 Mil. Pharmaniaga Bhd's average shareholder tangible equity for the quarter that ended in Mar. 2026 was RM298 Mil. Therefore, Pharmaniaga Bhd's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 42.23%.
The historical rank and industry rank for Pharmaniaga Bhd's Return-on-Tangible-Equity or its related term are showing as below:
XKLS:7081'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -122.38 Med: 26.13 Max: 91.83
Current: 87.68
During the past 13 years, Pharmaniaga Bhd's highest Return-on-Tangible-Equity was 91.83%. The lowest was -122.38%. And the median was 26.13%.
XKLS:7081's Return-on-Tangible-Equity is ranked better than 86.61% of 112
companies
in the Medical Distribution industry
Industry Median: 8.755
vs XKLS:7081: 87.68
Pharmaniaga Bhd (XKLS:7081) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Pharmaniaga Bhd Return-on-Tangible-Equity Related Terms
Pharmaniaga Bhd Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Pharmaniaga Bhd's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:7081 vs MCK, COR, CAH: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, Pharmaniaga Bhd's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaniaga Bhd Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Pharmaniaga Bhd's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Pharmaniaga Bhd's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 42.23% mean?
Pharmaniaga Bhd (XKLS:7081) has a Return-on-Tangible-Equity of 42.23% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Pharmaniaga Bhd and its competitors. This is 62% above median its historical median of 26.13. According to the industry distribution chart, Pharmaniaga Bhd ranks #15 out of 112 companies in the Medical Distribution industry, placing it in the top 13.4%.
Is Pharmaniaga Bhd's Return-on-Tangible-Equity too high?
Pharmaniaga Bhd's current Return-on-Tangible-Equity of 42.23% is 62% above median its 10-year median of 26.13. The Medical Distribution industry median Return-on-Tangible-Equity is 8.76. Pharmaniaga Bhd's value of 42.23% is 382.4% above this industry median. Based on the distribution chart, Pharmaniaga Bhd ranks #15 out of 112 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Pharmaniaga Bhd has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmaniaga Bhd's Return-on-Tangible-Equity compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Pharmaniaga Bhd ranks #15 out of 112 companies for Return-on-Tangible-Equity. This places Pharmaniaga Bhd in the top 13% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 8.76. Pharmaniaga Bhd's value of 42.23% is 382.4% above this benchmark. While the company's 10-year median is 26.13 vs. the industry median of 8.76, Pharmaniaga Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.76, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmaniaga Bhd's current Return-on-Tangible-Equity of 42.23% is 382.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Pharmaniaga Bhd and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmaniaga Bhd's current Return-on-Tangible-Equity is 42.23%, which is 62% above median its own 10-year median of 26.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaniaga Bhd stock overvalued right now?
Based on GuruFocus' analysis, Pharmaniaga Bhd (XKLS:7081) is currently considered Significantly Overvalued. The stock's GF Value™ is RM0.69, compared to a current price of RM1.18 — trading 71% above its estimated fair value. The current Return-on-Tangible-Equity is 42.23%, which is 62% above median its 10-year median of 26.13 and 382.4% above the Medical Distribution industry median of 8.76. Pharmaniaga Bhd's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Pharmaniaga Bhd (XKLS:7081), the current Return-on-Tangible-Equity is 42.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaniaga Bhd (XKLS:7081) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaniaga Bhd stock appears to be overvalued.
The current stock price of RM1.18 is trading 71% above its estimated GF Value™ of RM0.69.
GuruFocus considers Pharmaniaga Bhd to be Significantly Overvalued.
Key valuation signals for XKLS:7081:
Return-on-Tangible-Equity: 42.23% (62% above median its 10-year median of 26.13)
GF Value™: RM0.69 vs. price of RM1.18 (71% above fair value)
Industry Position: 382.4% above the Medical Distribution median (#15 of 112)
No single metric tells the full story. See the XKLS:7081 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaniaga Bhd is engaged in the manufacture of pharmaceuticals and medical devices. The company is also involved in logistics and distribution. The group operates in three segments - Logistics and distribution, Manufacturing in Malaysia, and Manufacturing and distribution in Indonesia. Maximum revenue is generated by the logistics and distribution segment in Malaysia. The Logistics and distribution segment is engaged in distribution, trading and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia.
45GF Score
Get the complete analysis for XKLS:7081
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7081 has been successfully added to your 
